vs
康耐视（CGNX）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
康耐视的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$252.3M vs $207.3M），康耐视净利率更高（12.9% vs -62.0%，领先75.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.9%），康耐视自由现金流更多（$72.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.4%）
康耐视（Cognex Corporation）是总部位于美国马萨诸塞州内蒂克的机器视觉系统、软件及传感器制造商，业务覆盖全球20余个国家和地区，为各工业领域客户提供高性能的视觉相关产品及解决方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CGNX vs RARE — 直观对比
营收规模更大
CGNX
是对方的1.2倍
$207.3M
营收增速更快
RARE
高出16.0%
9.9%
净利率更高
CGNX
高出75.0%
-62.0%
自由现金流更多
CGNX
多$173.1M
$-100.8M
两年增速更快
RARE
近两年复合增速
9.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $252.3M | $207.3M |
| 净利润 | $32.7M | $-128.6M |
| 毛利率 | 65.7% | — |
| 营业利润率 | 14.0% | -54.7% |
| 净利率 | 12.9% | -62.0% |
| 营收同比 | 9.9% | 25.9% |
| 净利润同比 | 15.2% | 3.5% |
| 每股收益（稀释后） | $0.20 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CGNXRARE
| Q4 25 | $252.3M | $207.3M | ||
| Q3 25 | $276.9M | $159.9M | ||
| Q2 25 | $249.1M | $166.5M | ||
| Q1 25 | $216.0M | $139.3M | ||
| Q4 24 | $229.7M | $164.6M | ||
| Q3 24 | $234.7M | $139.5M | ||
| Q2 24 | $239.3M | $147.0M | ||
| Q1 24 | $210.8M | $108.8M |
净利润CGNXRARE
| Q4 25 | $32.7M | $-128.6M | ||
| Q3 25 | $17.7M | $-180.4M | ||
| Q2 25 | $40.5M | $-115.0M | ||
| Q1 25 | $23.6M | $-151.1M | ||
| Q4 24 | $28.3M | $-133.2M | ||
| Q3 24 | $29.6M | $-133.5M | ||
| Q2 24 | $36.2M | $-131.6M | ||
| Q1 24 | $12.0M | $-170.7M |
毛利率CGNXRARE
| Q4 25 | 65.7% | — | ||
| Q3 25 | 67.6% | — | ||
| Q2 25 | 67.4% | — | ||
| Q1 25 | 66.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 67.9% | — | ||
| Q2 24 | 69.6% | — | ||
| Q1 24 | 67.3% | — |
营业利润率CGNXRARE
| Q4 25 | 14.0% | -54.7% | ||
| Q3 25 | 20.9% | -106.9% | ||
| Q2 25 | 17.4% | -64.8% | ||
| Q1 25 | 12.1% | -102.6% | ||
| Q4 24 | 13.4% | -74.3% | ||
| Q3 24 | 13.4% | -94.6% | ||
| Q2 24 | 16.1% | -79.1% | ||
| Q1 24 | 6.7% | -151.9% |
净利率CGNXRARE
| Q4 25 | 12.9% | -62.0% | ||
| Q3 25 | 6.4% | -112.8% | ||
| Q2 25 | 16.3% | -69.0% | ||
| Q1 25 | 10.9% | -108.5% | ||
| Q4 24 | 12.3% | -80.9% | ||
| Q3 24 | 12.6% | -95.7% | ||
| Q2 24 | 15.1% | -89.5% | ||
| Q1 24 | 5.7% | -156.8% |
每股收益（稀释后）CGNXRARE
| Q4 25 | $0.20 | $-1.28 | ||
| Q3 25 | $0.10 | $-1.81 | ||
| Q2 25 | $0.24 | $-1.17 | ||
| Q1 25 | $0.14 | $-1.57 | ||
| Q4 24 | $0.17 | $-1.34 | ||
| Q3 24 | $0.17 | $-1.40 | ||
| Q2 24 | $0.21 | $-1.52 | ||
| Q1 24 | $0.07 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $262.9M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.5B | $-80.0M |
| 总资产 | $2.0B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CGNXRARE
| Q4 25 | $262.9M | $421.0M | ||
| Q3 25 | $245.9M | $202.5M | ||
| Q2 25 | $179.3M | $176.3M | ||
| Q1 25 | $143.7M | $127.1M | ||
| Q4 24 | $186.1M | $174.0M | ||
| Q3 24 | $197.1M | $150.6M | ||
| Q2 24 | $176.6M | $480.7M | ||
| Q1 24 | $138.9M | $112.3M |
股东权益CGNXRARE
| Q4 25 | $1.5B | $-80.0M | ||
| Q3 25 | $1.5B | $9.2M | ||
| Q2 25 | $1.5B | $151.3M | ||
| Q1 25 | $1.4B | $144.2M | ||
| Q4 24 | $1.5B | $255.0M | ||
| Q3 24 | $1.6B | $346.8M | ||
| Q2 24 | $1.5B | $432.4M | ||
| Q1 24 | $1.5B | $140.3M |
总资产CGNXRARE
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $2.0B | $1.2B | ||
| Q2 25 | $2.0B | $1.3B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $2.0B | $1.5B | ||
| Q3 24 | $2.1B | $1.5B | ||
| Q2 24 | $2.0B | $1.6B | ||
| Q1 24 | $2.0B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $74.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $72.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 28.7% | -48.6% |
| 资本支出强度资本支出/营收 | 1.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.29× | — |
| 过去12个月自由现金流最近4个季度 | $236.8M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CGNXRARE
| Q4 25 | $74.9M | $-99.8M | ||
| Q3 25 | $87.5M | $-91.4M | ||
| Q2 25 | $42.6M | $-108.3M | ||
| Q1 25 | $40.5M | $-166.5M | ||
| Q4 24 | $51.4M | $-79.3M | ||
| Q3 24 | $56.3M | $-67.0M | ||
| Q2 24 | $27.8M | $-77.0M | ||
| Q1 24 | $13.6M | $-190.7M |
自由现金流CGNXRARE
| Q4 25 | $72.3M | $-100.8M | ||
| Q3 25 | $86.0M | $-92.7M | ||
| Q2 25 | $40.4M | $-110.7M | ||
| Q1 25 | $38.0M | $-167.8M | ||
| Q4 24 | $49.3M | $-79.5M | ||
| Q3 24 | $51.9M | $-68.6M | ||
| Q2 24 | $23.3M | $-79.0M | ||
| Q1 24 | $9.6M | $-193.9M |
自由现金流率CGNXRARE
| Q4 25 | 28.7% | -48.6% | ||
| Q3 25 | 31.1% | -58.0% | ||
| Q2 25 | 16.2% | -66.5% | ||
| Q1 25 | 17.6% | -120.5% | ||
| Q4 24 | 21.5% | -48.3% | ||
| Q3 24 | 22.1% | -49.2% | ||
| Q2 24 | 9.7% | -53.7% | ||
| Q1 24 | 4.5% | -178.2% |
资本支出强度CGNXRARE
| Q4 25 | 1.0% | 0.5% | ||
| Q3 25 | 0.5% | 0.8% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.2% | 1.0% | ||
| Q4 24 | 0.9% | 0.1% | ||
| Q3 24 | 1.9% | 1.2% | ||
| Q2 24 | 1.9% | 1.4% | ||
| Q1 24 | 1.9% | 3.0% |
现金转化率CGNXRARE
| Q4 25 | 2.29× | — | ||
| Q3 25 | 4.95× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.72× | — | ||
| Q4 24 | 1.81× | — | ||
| Q3 24 | 1.90× | — | ||
| Q2 24 | 0.77× | — | ||
| Q1 24 | 1.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CGNX
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
